3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
75
HER2-positive Breast Cancer
10
Neoplasms
8
Neoplasm Metastasis
4
Colonic Neoplasms
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Multiple Myeloma
3
Hematologic Neoplasms
3
Endometrial Neoplasms
3
Brain Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Urinary Bladder Neoplasms
2
Salivary Gland Neoplasms
2
Rectal Neoplasms
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Inflammatory Breast Neoplasms
2
HER2-positive Early Breast Cancer
2
Colorectal Neoplasms
2
Breast Diseases
2
Biliary Tract Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Interventions
pembrolizumab
16
Nivolumab
15
Ipilimumab
12
cemiplimab
10
aldesleukin
6
Interleukin-2
6
Cyclophosphamide
6
fludarabine
5
fludarabine phosphate
4
encorafenib
4
binimetinib
4
Blood Specimen Collection
4
avelumab
3
Sirolimus
3
trametinib
2
spartalizumab
2
lifileucel
2
dabrafenib
2
atezolizumab
2
Vemurafenib
2
Surgical Procedures, Operative
2
Specimen Handling
2
Radiotherapy
2
Prednisone
2
Niacinamide
2
Exercise
2
Everolimus
2
Dermoscopy
2
Biopsy
2
urelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
pertuzumab
×
1 year
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled